Quest Diagnostics Drug Testing Index[™]

Full year 2022 tables

Table 1. Annual Positivity Rates – Urine Drug Tests (For Combined U.S. Workforce)

Quest Diagnostics®

(More than 9.2 million tests from January to December 2022)

Year	Drug Positivity Rate			
1988	13.6%			
1989	12.7%			
1990	11.0%			
1991	8.8%			
1992	8.8%			
1993	8.4%			
1994	7.5%			
1995	6.7%			
1996	5.8%			
1997	5.0%			
1998	4.8%			
1999	4.6%			
2000	4.7%			
2001	4.6%			
2002	4.4%			
2003	4.5%			
2004	4.4%			
2005	4.0%			
2006	3.8%			
2007	3.8%			
2008	3.6%			
2009	3.6%			
2010	3.5%			
2011	3.5%			
2012	3.5%			
2013	3.7%			
2014	3.9%			
2015	4.0%			
2016	4.2%			
2017	4.2%			
2018	4.4%			
2019	4.5%			
2020	4.4%			
2021	4.6%			
2022	4.6%			

QuestDiagnostics.com/DTI

Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third party marks - (a) and [™] - are the property of their respective owners. (a) 2023 Quest Diagnostics Incorporated. All rights reserved. 5/2023

Table 2. Positivity Rates by Testing Category – Urine Drug Tests

Testing Category	2018	2019	2020	2021	2022
Federally Mandated, Safety-Sensitive Workforce	2.7%	2.4%	2.2%	2.2%	2.4%
General U.S. Workforce	5.1%	5.3%	5.5%	5.6%	5.7%
Combined U.S. Workforce	4.4%	4.5%	4.4%	4.6%	4.6%

Table 3. Positivity Rates by Testing Reason – Urine Drug Tests (For Federally Mandated, Safety-Sensitive Workforce)

(More than 2.9 million tests from January to December 2022)

Testing Reason	2018	2019	2020	2021	2022
Follow-Up	5.3%	5.1%	4.6%	4.3%	4.2%
For Cause	13.1%	13.0%	12.7%	13.8%	12.9%
Post-Accident	4.7%	4.5%	4.3%	4.4%	4.5%
Pre-Employment	2.6%	2.4%	2.1%	2.3%	2.5%
Random	2.4%	2.2%	2.0%	1.9%	1.9%
Return to Duty	5.5%	5.0%	4.5%	4.7%	4.9%

Table 4. Positivity Rates by Testing Reason – Urine Drug Tests(For General U.S. Workforce)

Testing Reason	2018	2019	2020	2021	2022
Follow-Up	8.4%	8.3%	7.1%	7.1%	7.3%
For Cause	33.7%	35.7%	34.7%	34.9%	38.6%
Post-Accident	8.4%	9.1%	9.5%	9.7%	10.3%
Pre-Employment	4.7%	4.9%	5.2%	5.4%	5.5%
Random	5.7%	5.6%	5.8%	5.8%	5.9%
Return to Duty	6.4%	6.8%	6.2%	6.3%	7.0%

Table 5. Positivity Rates by Drug Category – Urine Drug Tests (For Federally Mandated, Safety-Sensitive Workforce, as a percentage of all such tests)

Drug Category	2018	2019	2020	2021	2022
6-AM	0.013%	0.011%	0.008%	0.005%	0.003%
Amphetamines (Amphetamine/Methamphetamine)	0.68%	0.68%	0.64%	0.69%	0.75%
Cocaine	0.28%	0.25%	0.20%	0.21%	0.21%
Marijuana	0.88%	0.88%	0.79%	0.86%	0.98%
MDMA (MDMA/MDA)	0.003%	0.003%	0.002%	0.002%	0.003%
Opiates (Codeine/Morphine)	0.15%	0.12%	0.10%	0.08%	0.08%
Opiates (Hydrocodone/Hydromorphone)	0.45%	0.35%	0.30%	0.27%	0.24%
Oxycodones (Oxycodone/Oxymorphone)	0.34%	0.26%	0.21%	0.20%	0.18%
PCP	0.013%	0.011%	0.011%	0.010%	0.009%

(More than 2.9 million tests from January to December 2022)

Table 6. Positivity Rates by Drug Category – Urine Drug Tests(For General U.S. Workforce, as a percentage of all such tests)

Drug Category	2018	2019	2020	2021	2022
6-AM	0.03%	0.02%	0.018%	0.013%	0.006%
Amphetamines (Amphetamine/Methamphetamine)	1.2%	1.3%	1.3%	1.3%	1.5%
Barbiturates	0.22%	0.20%	0.20%	0.18%	0.17%
Benzodiazepines	0.52%	0.43%	0.39%	0.36%	0.35%
Cocaine	0.28%	0.27%	0.22%	0.21%	0.22%
Marijuana	2.8%	3.1%	3.6%	3.9%	4.3%
MDMA (MDMA/MDA)	0.006%	0.008%	0.010%	0.005%	0.004%
Methadone	0.18%	0.16%	0.14%	0.13%	0.12%
Opiates	0.31%	0.25%	0.21%	0.17%	0.16%
Opiates (Hydrocodone/Hydromorphone)	0.50%	0.37%	0.33%	0.32%	0.32%
Oxycodones (Oxycodone/Oxymorphone)	0.43%	0.34%	0.29%	0.29%	0.28%
PCP	0.011%	0.011%	0.009%	0.008%	0.008%
Propoxyphene	0.001%	0.000%	0.001%	0.000%	0000%

Table 7. Positivity Rates by Drug Category – Urine Drug Tests (For Combined U.S. Workforce, as a percentage of all such tests)

Drug Category	2018	2019	2020	2021	2022
6-AM	0.019%	0.015%	0.011%	0.008%	0.004%
Amphetamines (Amphetamine/Methamphetamine)	1.1%	1.1%	1.1%	1.1%	1.2%
Barbiturates	0.22%	0.20%	0.20%	0.18%	0.17%
Benzodiazepines	0.52%	0.43%	0.39%	0.36%	0.35%
Cocaine	0.28%	0.26%	0.21%	0.21%	0.22%
Marijuana	2.3%	2.5%	2.7%	2.9%	3.1%
MDMA (MDMA/MDA)	0.005%	0.005%	0.006%	0.004%	0.003%
Methadone	0.18%	0.16%	0.14%	0.13%	0.12%
Opiates	0.27%	0.22%	0.17%	0.15%	0.14%
Opiates (Hydrocodone/Hydromorphone)	0.46%	0.35%	0.31%	0.28%	0.26%
Oxycodones (Oxycodone/Oxymorphone)	0.38%	0.30%	0.24%	0.24%	0.23%
PCP	0.012%	0.011%	0.010%	0.008%	0.008%
Propoxyphene	0.001%	0.000%	0.001%	0.000%	0.000%

(More than 9.2 million tests from January to December 2022)

Table 8. Non-Negative Rates by Specimen Validity Test (SVT)² Category – Urine Drug Tests (For Federally Mandated, Safety-Sensitive Workforce, as a percentage of all such tests)

(More than 2.9 million tests from January to December 2022)

SVT Category	2018	2019	2020	2021	2022
Acid-Base	0.013%	0.010%	0.009%	0.009%	0.008%
Invalid	0.27%	0.21%	0.20%	0.26%	0.30%
Oxidizing Adulterants	0.000%	0.000%	0.000%	0.000%	0.000%
Substitution	0.019%	0.017%	0.016%	0.014%	0.017%

²Specimen validity testing is the evaluation of a specimen to determine if it is consistent with a normal human specimen. Tests for specimen validity include tests to determine whether a specimen is adulterated or substituted.

Table 9. Non-Negative Rates by Specimen Validity Test (SVT) Category – Urine Drug Tests (For General U.S. Workforce, as a percentage of all such tests)

SVT Category	2018	2019	2020	2021	2022
Acid-Base	0.010%	0.009%	0.009%	0.009%	0.009%
Invalid	0.21%	0.18%	0.17%	0.26%	0.31%
Oxidizing Adulterants	0.000%	0.000%	0.000%	0.000%	0.000%
Substitution	0.014%	0.015%	0.012%	0.013%	0.015%

(More than 6.3 million tests from January to December 2022)

QuestDiagnostics.com/DTI

Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third party marks - ® and ™ - are the property of their respective owners. © 2023 Quest Diagnostics Incorporated. All rights reserved. 5/2023

Table 10. Non-Negative Rates by Drug/SVT Category – Urine Drug Tests (For Federally Mandated, Safety-Sensitive Workforce, as a percentage of all non-negatives)

Drug/SVT Category	2018	2019	2020	2021	2022
6-AM	0.40%	0.40%	0.31%	0.18%	0.11%
Acid-Base	0.41%	0.34%	0.35%	0.33%	0.29%
Amphetamines (Amphetamine/Methamphetamine)	22.1%	24.3%	25.9%	26.6%	26.8%
Cocaine	9.2%	9.1%	8.1%	8.0%	7.6%
Invalid	8.7%	7.5%	7.9%	10.0%	10.9%
Marijuana	28.4%	31.5%	31.9%	33.1%	35.2%
MDMA (MDMA/MDA)	0.09%	0.09%	0.09%	0.08%	0.09%
Opiates (Codeine/Morphine)	4.7%	4.2%	3.9%	3.1%	3.0%
Opiates (Hydrocodone/Hydromorphone)	14.2%	12.3%	12.0%	10.2%	8.6%
Oxidizing Adulterants	0.000%	0.000%	0.000%	0.000%	0.000%
Oxycodones (Oxycodone/Oxymorphone)	10.9%	9.3%	8.5%	7.5%	6.5%
PCP	0.41%	0.41%	0.43%	0.38%	0.33%
Substituted	0.62%	0.61%	0.65%	0.56%	0.60%

(More than 80 thousand non-negative test results from January to December 2022)

Table 11. Non-Negative Rates by Drug/SVT Category – Urine Drug Tests(For General U.S. Workforce, as a percentage of all non-negatives)

(More than 390 thousand non-negative test results from January to December 2022)

Drug/SVT Category	2018	2019	2020	2021	2022
6-AM	0.12%	0.09%	0.08%	0.06%	0.03%
Acid-Base	0.17%	0.16%	0.15%	0.15%	0.14%
Amphetamines (Amphetamine/Methamphetamine)	22.3%	22.7%	21.5%	22.1%	23.6%
Barbiturates	2.5%	2.2%	2.0%	1.9%	1.6%
Benzodiazepines	5.8%	4.6%	3.9%	3.7%	3.4%
Cocaine	5.1%	4.7%	3.7%	3.4%	3.6%
Invalid	3.7%	3.1%	3.0%	4.3%	5.0%
Marijuana	49.3%	53.1%	57.8%	57.5%	56.1%
MDMA (MDMA/MDA)	0.04%	0.05%	0.06%	0.03%	0.03%
Methadone	1.9%	1.7%	1.4%	1.3%	1.1%
Opiates	5.6%	4.5%	3.5%	2.9%	2.6%
Opiates (Hydrocodone/Hydromorphone)	0.91%	0.87%	0.91%	0.85%	0.91%
Oxidizing Adulterants	0.000%	0.000%	0.000%	0.000%	0.000%
Oxycodones (Oxycodone/Oxymorphone)	2.2%	1.9%	1.6%	1.6%	1.6%
PCP	0.20%	0.20%	0.16%	0.13%	0.12%
Propoxyphene	0.010%	0.005%	0.007%	0.002%	0.003%
Substituted	0.24%	0.26%	0.21%	0.21%	0.24%

QuestDiagnostics.com/DTI

Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third party marks - ® and ™ - are the property of their respective owners. © 2023 Quest Diagnostics Incorporated. All rights reserved. 5/2023

5

Table 12. Non-Negative Rates by Drug/SVT Category – Urine Drug Tests (For Combined U.S. Workforce, as a percentage of all non-negatives)

Drug/SVT Category	2018	2019	2020	2021	2022
6-AM	0.17%	0.14%	0.12%	0.08%	0.04%
Acid-Base	0.21%	0.19%	0.18%	0.17%	0.17%
Amphetamines (Amphetamine/Methamphetamine)	22.3%	22.9%	22.2%	22.8%	24.2%
Barbiturates	2.0%	1.8%	1.7%	1.6%	1.3%
Benzodiazepines	4.8%	3.9%	3.3%	3.1%	2.8%
Cocaine	5.8%	5.4%	4.4%	4.1%	4.2%
Invalid	4.5%	3.8%	3.8%	5.2%	6.0%
Marijuana	45.8%	49.7%	53.6%	53.7%	52.6%
MDMA (MDMA/MDA)	0.05%	0.06%	0.07%	0.04%	0.04%
Methadone	1.6%	1.4%	1.1%	1.1%	0.93%
Opiates	5.5%	4.4%	3.6%	2.9%	2.6%
Opiates (Hydrocodone/Hydromorphone)	3.2%	2.7%	2.7%	2.3%	2.2%
Oxidizing Adulterants	0.000%	0.000%	0.000%	0.000%	0.000%
Oxycodones (Oxycodone/Oxymorphone)	3.7%	3.1%	2.7%	2.5%	2.4%
PCP	0.24%	0.23%	0.20%	0.17%	0.16%
Propoxyphene	0.008%	0.004%	0.006%	0.002%	0.003%
Substituted	0.31%	0.31%	0.28%	0.26%	0.30%

(More than 440 thousand non-negative test results from January to December 2022)

Table 13. Positivity Rates by Testing Category – Oral Fluid Drug Tests (For General U.S. Workforce)

(More than 1.4 million tests from January to December 2022)

2018	2019	2020	2021	2022
10.2%	10.5%	13.6%	7.3%	3.2%

Table 14. Positivity Rates by Testing Reason – Oral Fluid Drug Tests(For General U.S. Workforce)

(More than 1.4 million tests from January to December 2022)

Testing Reason	2018	2019	2020	2021	2022
Post-Accident	5.8%	5.4%	5.8%	8.5%	9.9%
Pre-Employment	10.5%	10.7%	13.9%	7.1%	2.8%
Random	6.2%	6.0%	5.6%	5.5%	4.2%

Table 15. Positivity Rates by Drug Category – Oral Fluid Drug Tests(For General U.S. Workforce)

Drug Category	2018	2019	2020	2021	2022
Amphetamine	0.73%	0.67%	0.71%	0.80%	0.74%
Cocaine/Metabolite	0.59%	0.57%	0.58%	0.85%	0.83%
Marijuana	8.7%	9.1%	12.3%	14.8%	10.4%
Methamphetamines	0.47%	0.49%	0.53%	0.67%	0.70%
Opiates	0.44%	0.35%	0.31%	0.27%	0.22%
Oxycodones	0.31%	0.28%	0.24%	0.24%	0.23%
PCP	0.04%	0.05%	0.04%	0.05%	0.04%

Table 16. Positivity Rates by Testing Category – Hair Drug Tests (For General U.S. Workforce)

(Nearly 80 thousand tests from January to December 2022)

2018	2019	2020	2021	2022
10.9%	11.2%	12.8%	13.1%	13.1%

Table 17. Positivity Rates by Testing Reason – Hair Drug Tests(For General U.S. Workforce)

(Nearly 80 thousand tests from January to December 2022)

Testing Reason	2018	2019	2020	2021	2022
Pre-Employment	9.4%	9.0%	9.8%	10.1%	9.9%
Random	10.1%	12.0%	16.7%	18.3%	19.8%

Table 18a. Positivity Rates by Drug Category – Hair Drug Tests(For General U.S. Workforce)

(Old Technology)

Drug Category	2018	2019	2020	2021
Amphetamines (Methamphetamine)	2.0%	2.4%	2.6%	2.4%
Cocaine	3.4%	3.2%	3.2%	2.8%
Marijuana	6.8%	7.1%	8.7%	9.8%
Opiates	0.39%	0.32%	0.29%	0.20%
PCP	0.016%	0.012%	0.03%	0.012%

Table 18b. Positivity Rates by Drug Category – Hair Drug Tests(For General U.S. Workforce)

(Nearly 80 thousand tests from January to December 2022 – New Technology)

Drug Category	2021	2022
6-AM	0.08%	0.05%
Amphetamine	1.8%	1.7%
Benzoylecgonine	1.1%	1.1%
Cocaine	2.7%	2.9%
Marijuana	9.5%	10.3%
MDA	0.03%	0.02%
MDMA	0.13%	0.08%
Methamphetamine	2.1%	1.9%
Opiates (Codeine/Hydrocodone)	0.37%	0.29%
Opiates (Morphine/Hydromorphone)	0.06%	0.04%
Oxycodone	 0.60%	0.56%
Oxymorphone	 0.03%	0.05%
PCP	0.02%	0.02%

Table 19. Post-Accident vs. Pre-Employment Positivity Rates for Marijuana – Urine Drug Tests (For Federally Mandated, Safety-Sensitive Workforce, as a percentage of all such tests)

Drug Category	2014	2015	2016	2017	2018	2019	2020	2021	2022
Pre-Employment (PE)	0.88%	0.90%	0.93%	0.99%	1.0%	1.0%	0.95%	1.1%	1.3%
Post-Accident (PA)	1.0%	1.1%	1.2%	1.3%	1.5%	1.6%	1.6%	1.8%	2.1%
% Difference PE vs. PA	13.6%	22.2%	29.0%	31.3%	50.0%	60.0%	68.4%	63.6%	61.5%

(More than 2.9 million tests from January to December 2022)

Table 20. Post-Accident vs. Pre-Employment Positivity Rates for Marijuana – Urine Drug Tests (For General U.S. Workforce, as a percentage of all such tests)

(More than 6.3 million tests from January to December 2022)

Drug Category	2014	2015	2016	2017	2018	2019	2020	2021	2022
Pre-Employment (PE)	2.2%	2.3%	2.4%	2.6%	2.8%	3.1%	3.7%	4.1%	4.6%
Post-Accident (PA)	3.3%	3.5%	3.8%	4.2%	4.8%	5.7%	6.4%	6.7%	7.3%
% Difference PE vs. PA	50.0%	52.2%	58.3%	61.5%	71.4%	83.9%	73.0%	63.4%	58.7%

Table 21. Post-Accident vs. Pre-Employment Positivity Rates for Cocaine – Urine Drug Tests (For Federally Mandated, Safety-Sensitive Workforce, as a percentage of all such tests)

(More than 2.9 million tests from January to December 2022)

Drug Category	2018	2019	2020	2021	2022
Pre-Employment (PE)	0.31%	0.27%	0.21%	0.21%	0.21%
Post-Accident (PA)	0.55%	0.47%	0.44%	0.46%	0.43%
% Difference PE vs. PA	77.4%	74.1%	109.5%	119.0%	104.8%

Table 22. Post-Accident vs. Pre-Employment Positivity Rates for Cocaine – Urine Drug Tests (For General U.S. Workforce, as a percentage of all such tests)

Drug Category	2018	2019	2020	2021	2022
Pre-Employment (PE)	0.24%	0.23%	0.18%	0.18%	0.20%
Post-Accident (PA)	0.71%	0.73%	0.63%	0.66%	0.66%
% Difference PE vs. PA	195.8%	217.4%	250.0%	266.7%	230.0%

Table 23. Post-Accident vs. Pre-Employment Positivity Rates for Opiates(Hydrocodone/Hydromorphone) – Urine Drug Tests(For Federally Mandated, Safety-Sensitive Workforce, as a percentage of all such tests)

Drug Category	2018	2019	2020	2021	2022
Pre-Employment (PE)	0.36%	0.27%	0.22%	0.21%	0.18%
Post-Accident (PA)	1.1%	0.89%	0.81%	0.75%	0.68%
% Difference PE vs. PA	205.6%	229.6%	268.2%	257.1%	277.8%

(More than 2.9 million tests from January to December 2022)

Table 24. Post-Accident vs. Pre-Employment Positivity Rates for Opiates(Hydrocodone/Hydromorphone) – Urine Drug Tests(For General U.S. Workforce, as a percentage of all such tests)

(More than 6.3 million tests from January to December 2022)

Drug Category	2018	2019	2020	2021	2022
Pre-Employment (PE)	0.35%	0.26%	0.23%	0.24%	0.24%
Post-Accident (PA)	1.2%	1.1%	0.95%	1.0%	1.0%
% Difference PE vs. PA	242.9%	323.1%	313.0%	316.7%	316.7%

Table 25. Post-Accident vs. Pre-Employment Positivity Rates for Oxycodones (Oxycodone/Oxymorphone) – Urine Drug Tests (For Federally Mandated, Safety-Sensitive Workforce, as a percentage of all such tests)

(More than 2.9 million tests from January to December 2022)

Drug Category	2018	2019	2020	2021	2022
Pre-Employment (PE)	0.30%	0.22%	0.17%	0.17%	0.16%
Post-Accident (PA)	0.77%	0.58%	0.52%	0.50%	0.44%
% Difference PE vs. PA	156.7%	163.6%	205.9%	194.1%	175.0%

Table 26. Post-Accident vs. Pre-Employment Positivity Rates for Oxycodones (Oxycodone/Oxymorphone) – Urine Drug Tests (For General U.S. Workforce, as a percentage of all such tests)

(More than 6.3 million tests from January to December 2022)

Drug Category	2018	2019	2020	2021	2022
Pre-Employment (PE)	0.35%	0.28%	0.24%	0.24%	0.24%
Post-Accident (PA)	0.95%	0.77%	0.62%	0.72%	0.69%
% Difference PE vs. PA	171.4%	175.0%	158.3%	200.0%	187.5%

11

Table 27. Marijuana Positivity by 2021 State Legalized Use Status – Urine Drug Tests (For Federally Mandated, Safety-Sensitive Workforce, as a percentage of all tests for Marijuana Metabolite)

Drug Category	2014	2015	2016	2017	2018	2019	2020	2021	2022
Recreational Use	0.71%	0.72%	0.81%	0.87%	0.93%	0.94%	0.86%	0.94%	1.1%
Medical Use Only	0.74%	0.74%	0.81%	0.85%	0.87%	0.92%	0.81%	0.85%	0.90%
Neither Recreational nor Medical Use	0.67%	0.69%	0.75%	0.83%	0.88%	0.83%	0.73%	0.79%	0.89%
National	0.71%	0.71%	0.78%	0.84%	0.88%	0.88%	0.79%	0.86%	0.98%

(More than 2.9 million tests from January to December 2022)

Table 28. Marijuana Positivity by 2021 State Legalized Use Status - Urine Drug Tests (For General U.S. Workforce, as a percentage of all tests for Marijuana Metabolite)

Drug Category	2014	2015	2016	2017	2018	2019	2020	2021	2022
Recreational Use	2.3%	2.4%	2.6%	2.7%	3.1%	3.8%	4.4%	5.1%	5.7%
Medical Use Only	2.0%	2.1%	2.1%	2.2%	2.5%	2.8%	3.2%	3.6%	3.9%
Neither Recreational nor Medical Use	2.7%	2.6%	2.7%	2.8%	2.7%	2.7%	3.0%	3.0%	3.1%
National	2.4%	2.4%	2.5%	2.6%	2.8%	3.1%	3.6%	3.9%	4.3%